(Q39520099)

English

Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice

scientific article published on 13 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 September 2017

Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice (English)

1 reference

Europe PubMed Central

12 September 2017

0 references

Streptococcus pneumoniae

1 reference

based on heuristic

inferred from title

author name string

Chung Truong Nguyen

1

1 reference

Europe PubMed Central

12 September 2017

Soo Young Kim

2

1 reference

Europe PubMed Central

12 September 2017

Myoung Suk Kim

3

1 reference

Europe PubMed Central

12 September 2017

Shee Eun Lee

4

1 reference

Europe PubMed Central

12 September 2017

Joon Haeng Rhee

5

1 reference

Europe PubMed Central

12 September 2017

language of work or name

0 references

publication date

13 June 2011

1 reference

Europe PubMed Central

12 September 2017

1 reference

Europe PubMed Central

12 September 2017

29

1 reference

Europe PubMed Central

12 September 2017

34

1 reference

Europe PubMed Central

12 September 2017

5731-5739

1 reference

Europe PubMed Central

12 September 2017

Attacking the pneumococcus -- a hundred years' war.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

The prevention of pneumococcal disease in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

The 23-Valent Pneumococcal Polysaccharide Vaccine. Part II. A Cost-Effectiveness Analysis for Invasive Disease in the Elderly in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Considerations for Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with Emphasis on the Cross-Reactive Types Within Groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Strategies for the control of pneumococcal diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Characterization of selected strains of pneumococcal surface protein A

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Epitope analyses of pneumococcal surface protein A: a combination of two monoclonal antibodies detects 94% of clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Mucosal vaccines: the promise and the challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Inhibition of airway allergic disease by co-administration of flagellin with allergen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES: INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Epitope mapping of pneumococcal surface protein A of strain Rx1 using monoclonal antibodies and molecular structure modelling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Nuclear factor-kappa B plays a major role in the regulation of chemokine expression of HeLa cells in response to Toxoplasma gondii infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Capsule genes of Streptococcus pneumoniae influence growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

The vaccine potential of Streptococcus pneumoniae surface lectin- and non-lectin proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Structure of the bacterial flagellar protofilament and implications for a switch for supercoiling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Flagellin as a good carrier and potent adjuvant for Th1 response: study of mice immune response to the p27 (Rv2108) Mycobacterium tuberculosis antigen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

Clinical and epidemiologic studies of pneumococcal infection in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

based on heuristic

inferred from DOI database lookup

Cloning and nucleotide sequence analysis of psaA, the Streptococcus pneumoniae gene encoding a 37-kilodalton protein homologous to previously reported Streptococcus sp. adhesins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

based on heuristic

inferred from DOI database lookup

Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.095

7 January 2021

based on heuristic

inferred from DOI database lookup

A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1093/OXFORDJOURNALS.AJE.A118408

Identifiers

10.1016/J.VACCINE.2011.05.095

1 reference

Europe PubMed Central

12 September 2017

1 reference

Europe PubMed Central

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39520099&oldid=1833932479"